Non Hodgkin's Lymphoma
Cyberfamily

Search    

 MCL treatment abstracts   

Mantle Cell Lymphoma medical abstracts

1. Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma

2. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL

3. Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope

4. Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma

5. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

6. Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma.

7. Thalidomide and Rituximab Effective for Mantle Cell Lymphoma Researchers from Austria have reported that the combination of thalidomide and rituximab is effective for the treatment of relapsed/refractory mantle cell lymphoma with a low toxicity profile. The details of this study appeared in the October 15, 2004 issue of Blood

8. Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free Survival in Mantle Cell Lymphoma 

9. Rituximab/Chemotherapy Induction Treatment Followed by High-Dose Therapy and Autologous Transplantation in Patients with Mantle Cell Lymphoma  

10. Rituximab and Stem Cell Transplantation Produces Durable Remissions in Mantle Cell Lymphoma

11. Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma 

12. A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL) 

13. Phase II Trial of Bortezomib in Mantle Cell Lymphoma 

14. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

© 2006 NHL Cyberfamily All Rights Reserved.
Web design by Long2 Consulting